TWI471329B - 噻唑基及唑基－異喹啉酮及其使用方法 - Google Patents

噻唑基及唑基－異喹啉酮及其使用方法 Download PDF

Info

Publication number
TWI471329B
TWI471329B TW98120713A TW98120713A TWI471329B TW I471329 B TWI471329 B TW I471329B TW 98120713 A TW98120713 A TW 98120713A TW 98120713 A TW98120713 A TW 98120713A TW I471329 B TWI471329 B TW I471329B
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
thiazolo
hydroxy
Prior art date
Application number
TW98120713A
Other languages
English (en)
Chinese (zh)
Other versions
TW201002725A (en
Inventor
羅貝托 裴利奇亞力
佛雷維歐 摩洛尼
亞當 馬修 吉伯特
Original Assignee
羅貝托 裴利奇亞力
佛雷維歐 摩洛尼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 羅貝托 裴利奇亞力, 佛雷維歐 摩洛尼 filed Critical 羅貝托 裴利奇亞力
Publication of TW201002725A publication Critical patent/TW201002725A/zh
Application granted granted Critical
Publication of TWI471329B publication Critical patent/TWI471329B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW98120713A 2008-06-19 2009-06-19 噻唑基及唑基－異喹啉酮及其使用方法 TWI471329B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19

Publications (2)

Publication Number Publication Date
TW201002725A TW201002725A (en) 2010-01-16
TWI471329B true TWI471329B (zh) 2015-02-01

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
TW98120713A TWI471329B (zh) 2008-06-19 2009-06-19 噻唑基及唑基－異喹啉酮及其使用方法

Country Status (12)

Country Link
US (3) US8299090B2 (enExample)
EP (2) EP2303895B1 (enExample)
JP (2) JP5564495B2 (enExample)
AR (1) AR072265A1 (enExample)
AU (1) AU2009260060B2 (enExample)
CA (1) CA2728454C (enExample)
DK (1) DK2303895T3 (enExample)
ES (1) ES2530815T3 (enExample)
HK (1) HK1212698A1 (enExample)
SA (1) SA109300394B1 (enExample)
TW (1) TWI471329B (enExample)
WO (1) WO2009155402A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036599A1 (en) * 2000-10-31 2002-05-10 Smithkline Beecham P.L.C. Thieno[2,3-c]isoquinolines for use as inhibitors of parp
WO2007149907A2 (en) * 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
ATE533812T1 (de) 2005-08-01 2011-12-15 Wietek Holding Gmbh Verfahren zur rezyklierung von kunststoff
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036599A1 (en) * 2000-10-31 2002-05-10 Smithkline Beecham P.L.C. Thieno[2,3-c]isoquinolines for use as inhibitors of parp
WO2007149907A2 (en) * 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chiarugi A., et al.," Novel Isoquinolinone-Derived Inhibitors of Poly(ADP-ribose) Polymerase-1: Pharmacological Characterization and Neuroprotective Effects in an in Vitro Model of Cerebral Ischemia", J Pharmacol Exp Ther., 2003, Vol.305, No.3, P.943-949. *

Also Published As

Publication number Publication date
JP2011525185A (ja) 2011-09-15
WO2009155402A1 (en) 2009-12-23
JP5564495B2 (ja) 2014-07-30
TW201002725A (en) 2010-01-16
US8299090B2 (en) 2012-10-30
HK1156310A1 (en) 2012-06-08
JP2014122242A (ja) 2014-07-03
US20130059843A1 (en) 2013-03-07
US20150133443A1 (en) 2015-05-14
AU2009260060A1 (en) 2009-12-23
AR072265A1 (es) 2010-08-18
EP2896626A1 (en) 2015-07-22
CA2728454C (en) 2017-01-17
HK1212698A1 (en) 2016-06-17
EP2303895B1 (en) 2014-09-24
CA2728454A1 (en) 2009-12-23
US20090318442A1 (en) 2009-12-24
AU2009260060B2 (en) 2015-01-22
DK2303895T3 (en) 2015-01-12
US9265769B2 (en) 2016-02-23
SA109300394B1 (ar) 2013-01-22
EP2303895A1 (en) 2011-04-06
ES2530815T3 (es) 2015-03-05
US8906935B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
TWI471329B (zh) 噻唑基及唑基－異喹啉酮及其使用方法
EP2385039B1 (en) 2-Iminoisoindolinone derivatives as thrombin receptor antagonists
EA016079B1 (ru) Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2004520273A (ja) Ｐａｒｐの阻害剤として用いるためのチエノ［２，３−ｃ］イソキノリン
TW201636329A (zh) 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
TWI491613B (zh) 噻吩基及呋喃基－異喹啉酮及其使用方法
JPWO2002079204A1 (ja) ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
HK1156310B (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
CN114671856A (zh) 多取代的尿嘧啶衍生物及其用途
CN121219288A (zh) 用于治疗疾病或障碍的萘啶酮衍生物
HK40069843A (en) Estrogen-related receptor alpha (erralpha) modulators
JP2009514984A (ja) 新規化合物
JP2002519346A (ja) １−（ベンゾチアゾール−２−イル）−４−（１−フェニルメチル）ピペラジン：ドーパミン受容体サブタイプ特異リガンド

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees